Navigation Links
Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
Date:4/21/2009

OXFORD, England, April 21 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced today that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.

The lastest study, which is underway in Canada, will enrol 48 patients with confirmed cat allergies and cat-allergen induced asthma. The randomised, double-blind, placebo-controlled trial will study the use of a standard dose of ToleroMune administered over a number of weeks. This is in marked contrast to most current immunotherapy treatments, which require carefully escalated weekly dosing over many months, followed by further monthly doses for several years, to reduce the risk of potentially serious adverse reactions. During the study, each patient will receive a controlled 'challenge' with cat allergens, both before and after treatment, to allow investigators to assess the effect of ToleroMune therapy compared to placebo.

"This study marks an important milestone in the development of our ToleroMune anti-allergy technology, as it extends our target patient group to those with more serious allergies that can result in asthma attacks," said Steve Harris, Circassia's CEO. "We believe that Circassia's allergy therapies will offer patients important clinical benefits. Most existing treatments address either symptoms only, or require lengthy and complicated dosing because of their potential to lead to serious and even lifethreatening reactions. In contrast, our clinical results show that ToleroMune has the potential to treat the underlying causes of allergies, using short and simple courses of treatment that minimize the risk of severe side effects."

Abou
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
4. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
5. Study Says Allergy Shots Help Children, Reduce Health Care Costs
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
9. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
10. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... ... Meeting - A cumulative forty-five percent (45%) of patients ... medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative 81%) patients with ...
... La ... ... 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a,biopharmaceutical ... research organization, today announced,that an agreement has been executed licensing classes ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... watching World Cup highlights, Brian Williams refreshing old school ... positions on railings. A University of Colorado Cancer Center ... shows that YouTube also allows researchers, journals, and health ... of skin cancer and prevention. , "No matter what ... how we communicate around the world," says Chante Karimkhani, ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... kidney and heart disease have raised concerns about the ... in the first study to look closely at this ... the University of Pennsylvania report that older kidney donors ... cardiovascular health as very healthy older people who did ... increasing organ transplant waitlists, the authors of the study ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... ... important questions to ask when choosing an alcohol rehab centre. , ... London, UK (PRWEB) June 17, 2009 -- Linwood Group announce that there ... in getting someone who is struggling with drink on the road to recovery. Having treatment in ...
... ... of leading cardiovascular disease centers in the United States exploring the efficacy of a ... treatment of patients with advanced congestive heart failure (CHF) who are on the waiting ... ...
... Health reform must deliver "evolutionary change" says new leader of ... J. James Rohack, M.D., a cardiologist from Bryan, Texas, was ... Association (AMA), the nation,s largest and most influential physician organization. ... ) , , In his inaugural address as ...
... , Independence Blue Cross and Philadelphia Business Journal to ... June 16 Americans spend more ... costs continuing to climb, many employers are looking for ways to ... In conjunction with Philadelphia Business Journal, Independence Blue Cross (IBC) is ...
... statin drugs, such as Lipitor (atorvastatin), does not lower the ... of more than 3,000 Group Health patients published online on ... ,s June 20 print issue. "Prior research based on ... statins as a way to prevent and treat infections including ...
... , Reporting System Provides Information to Improve Quality of , ... , WASHINGTON, June 16 URAC , ... CARF International , a premier, global, independent accreditor ... for case management professionals. The uSPEQ(R)/URAC Participant Experience ...
Cached Medicine News:Health News:Linwood Group Research Suggests 3 Questions Everyone Should Ask When Choosing an Alcoholic Residential Centre 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 2Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 3Health News:AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure 4Health News:AMA Inaugurates J. James Rohack as President 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 2Health News:Employee Health and Reducing Health Care Costs Focus of Working Wellness Expo June 17 3Health News:Statins don't lower risk of pneumonia in elderly 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 2Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 3Health News:URAC and CARF International Announce New Survey Tool for Health Care Case Management Studies 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: